Article Figures & Data
Figures
- Figure 1.
After 4 wk of induction with gemcitabine, the cohort 2 showed a plateau in effect. After re-randomization, the group released from gemcitabine (3) rapidly regrew, as did the group receiving cyclopamine (5). The group that continued gemcitabine (4) remained in an activity plateau. Only the combination therapy group (6) showed incremental effect, and these tumors homogeneously regressed to 50% of the initial size after 4 wk. Bars, SD.
- Figure 2.
A, immunohistochemical assessment of CD24, CD44, and ALDH by immunohistochemistry. CD44 presented a flat staining that was not different between groups. However, both CD24 and ALDH had a pattern consisting in inversely intense staining with tumor size, with maximal staining in gemcitabine-treated and gemcitabine + cyclopamine-treated groups. B, tumor growth, mouse nestin expression, cytoplasmic CD24, ALDH by reverse transcription-PCR and immunohistochemistry, and GLI1 mRNA expression. ALDH by immunohistochemistry was particularly differentiating as the low-level expression followed an all-or-nothing pattern. ALDH was only positive in 2% of the cells in the gemcitabine-treated groups. In the group where gemcitabine is ceased, the TSC markers (both CD24 and ALDH) decreased back to the levels of the untreated group, suggesting a repopulation of proliferating cells and a dilution of the TSC-enriching effect.
Related Data
Volume 8, Issue 2
